Did you miss our live company presentation with NanoEcho’s CEO, Linda Persson, yesterday? No worries, you can watch it afterwards. The presentation is now also subtitled.
NanoEcho is currently conducting a new share issue to enter the clinical phase with our patented diagnostic method. The goal is to improve healthcare by providing patients with rectal cancer a more accurate diagnosis and personalised treatment.
Learn more about the ongoing share issue: https://lnkd.in/dH_uUs5h.
NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.
We use cookies to enhance your experience on our website and analyze our traffic. By clicking ‘Accept,’ you consent to our use of cookies. You can learn more about the types of cookies we use and how to manage them in our privacy policy.